SCHEMBL30135904

SCHEMBL30135904

O=C(NC1CCN(CC2CN(c3ccc([N+](=O)[O-])cc3F)C2)CC1)OCc1ccccc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SIGMAR1 Q99720 4/20 0.47
CTSL P07711 1/20 0.45
CTSB P07858 1/20 0.45
CTSK P43235 1/20 0.45
ALDH1A1 P00352 3/20 0.45
MAPT P10636 2/20 0.45
LMNA P02545 2/20 0.45
GAA P10253 1/20 0.43
POLB P06746 1/20 0.42
BRD4 O60885 1/20 0.42
BRD2 P25440 1/20 0.42
BRD3 Q15059 1/20 0.42
CHRM4 P08173 1/20 0.42
TSHR P16473 1/20 0.42
DPP4 P27487 2/20 0.42
KCNH2 Q12809 2/20 0.42
DPP7 Q9UHL4 2/20 0.42
TMEM97 Q5BJF2 1/20 0.41
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30135849 0.88 CTSL (0.48) SIGMAR1CTSLCTSBCTSKALDH1A1
SCHEMBL30965749 0.88 CHRM4 (0.50) SIGMAR1ALDH1A1MAPTLMNAPOLB
SCHEMBL31334781 0.85 MAPT (0.46) SIGMAR1CTSLCTSBCTSKALDH1A1
SCHEMBL30135712 0.84 MAPT (0.45) SIGMAR1CTSLCTSBCTSKALDH1A1
SCHEMBL30965765 0.79 MAPT (0.44) ALDH1A1MAPTLMNAPOLBBRD4
SCHEMBL30135967 0.78 CTSL (0.39) CTSLCTSBCTSKALDH1A1GAA
SCHEMBL30136056 0.78 DDB1 (0.41) CTSLCTSBCTSKALDH1A1GAA
SCHEMBL25305374 0.78 POLB (0.51) ALDH1A1MAPTLMNAPOLBTSHR
SCHEMBL30981394 0.78 SIGMAR1 (0.52) SIGMAR1CTSLCTSBCTSKALDH1A1
SCHEMBL25935098 0.78 SMPD3 (0.44) CTSLCTSBCTSKALDH1A1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250101025-A1 NOVEL PLK1 DEGRADATION INDUCING COMPOUND UPPTHERA, INC. (KR) 2025-03-27 US disclosed
EP-4384521-A1 NOVEL PLK1 DEGRADATION INDUCING COMPOUND Uppthera, Inc. (KR) 2024-06-19 EP disclosed
WO-2023017446-A1 NOVEL PLK1 DEGRADATION INDUCING COMPOUND UPPTHERA, INC. (KR) 2023-02-16 WO disclosed
WO-2023018237-A1 NOVEL PLK1 DEGRADATION INDUCING COMPOUND UPPTHERA, INC. (KR) 2023-02-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250101025-A1 NOVEL PLK1 DEGRADATION INDUCING COMPOUND PLK1, BUB1B, BUB1 SIGMAR1 4265/4885CTSL 2369/4885CTSB 2194/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.